| Zogenix is a global pharmaceutical company engaged in developing and commercializing therapies to improve the lives of patients and their families living with rare diseases. Co. is focused on developing and commercializing Fintepla, a low-dose fenfluramine, for pediatric epilepsy disorders and MT1621 for mitochondrial depletion disease, thymidine kinase 2 deficiency. In the United Kingdom, Fintepla is under late-stage development in Japan for the treatment of seizures associated with Dravet syndrome, a pediatric epilepsy disorder. Fintepla is also under late-stage development for the treatment of seizures associated with Lennox-Gastaut syndrome, another form of childhood-onset epilepsy. We show 28 historical shares outstanding datapoints in our coverage of ZGNX's shares outstanding history.|
Understanding the changing numbers of ZGNX shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like ZGNX versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching ZGNX by allowing them to research ZGNX shares outstanding history
as well as any other stock in our coverage universe.